How to Implement Generative AI in Biopharma: A Step‑by‑Step Approach

Описание и применение

Внедрение генеративного ИИ в биофармацевтике через поэтапный подход позволяет ускорить подготовку документов, снизить время расследования отклонений на 40 % и повысить эффективность специалистов, соблюдая требования GMP и регуляторных органов.

Задача

Implementing generative AI in GMP‑regulated biopharma without disrupting validated processes or creating compliance headaches.

Результат

Reduced deviation investigation cycle time by 40%, achieved 91% minor‑edit rate on AI drafts, and enabled scalable AI augmentation across documentation workflows.

Рабочий процесс

• Identify high‑value, low‑risk starting points (e.g., deviation investigation reports).
• Establish data governance and privacy controls, create synthetic datasets, and secure on‑premise deployment.
• Design human‑in‑the‑loop workflows with a three‑step review process (model draft → quality engineer → QA manager).
• Validate the model output with accuracy, robustness, bias, and documentation reviews, aiming for ≥85% minor‑edit rate.
• Pilot with a cross‑functional team (quality engineers, manufacturing supervisors, QA managers) over 90 days, integrating via a custom QMS plugin.
• Scale based on demonstrated ROI to related applications (batch record summaries, tech transfer docs, change control narratives).

Доказательства

We defined acceptance criteria: 85% of AI-generated narratives must require only minor edits (no more than 15% content change) when reviewed by SMEs. The pilot exceeded this, hitting 91% on the hold-out set.

We cut deviation investigation cycle time by 40% and freed quality specialists to focus on root cause analysis rather than report formatting.